title: Randomised placebo-controlled trial of recombinant interleukin-2 in chronic uraemic patients who are non-responders to hepatitis B vaccine.
abstract: Natural interleukin-2 at low dose has been reported to overcome the non-responsiveness of patients with chronic uraemia to hepatitis B vaccine. Therefore, we revaccinated 52 previous such non-responders (24 on maintenance dialysis) with 20 micrograms of recombinant preS2-containing hepatitis B vaccine with human recombinant interleukin-2 (1 MU) or placebo (randomly allocated). Seroconversion rates (74 vs 80%, respectively) and proportion of patients who elicited anti-HBs titres of 10 mlU/mL or more (56 vs 68%) were similar in both groups. Our results do not confirm local injection of interleukin-2 as an effective immunoadjuvant to hepatitis B vaccine in uraemic patients.
authors.affiliation: Department of Nephrology, Hôpital Necker, Paris, France.
authors.forename: P
authors.initials: P
authors.lastname: Jungers
authors.forename: P
authors.initials: P
authors.lastname: Devillier
authors.forename: H
authors.initials: H
authors.lastname: Salomon
authors.forename: J E
authors.initials: JE
authors.lastname: Cerisier
authors.forename: A M
authors.initials: AM
authors.lastname: Courouce
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002908:Chronic Disease; D005260:Female; D006510:Hepatitis B Antibodies / Q000097:blood*; D017325:Hepatitis B Vaccines / Q000008:administration & dosage / Q000276:immunology*; D006801:Humans; D007117:Immunization, Secondary; D007376:Interleukin-2 / Q000008:administration & dosage* / Q000276:immunology; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000276:immunology; D006435:Renal Dialysis; D014511:Uremia / Q000276:immunology*
chemical_list: D000276:Adjuvants, Immunologic; D006510:Hepatitis B Antibodies; D017325:Hepatitis B Vaccines; D007376:Interleukin-2; D011994:Recombinant Proteins